Nona Biosciences announced the expansion of its integrated discovery and development framework to support early clinical development and Investigator-Initiated Trials (IITs). This expansion extends Nona's capabilities beyond discovery and IND-enabling activities to further strengthen CMC development, toxicology and GMP manufacturing capabilities. Through strategic partnerships, platform acquisitions and internal technology innovations, Nona will enable global biopharmaceutical companies to accelerate the clinical trial initiation with rigorous scientific and quality standards.

The expanded framework builds upon Nona's proprietary platforms, including Harbour Mice, HBICE, Hu-mAtrIx, NonaCarFx and Modalities-on-Demand and integrates strengthened preclinical and early clinical development capabilities across CMC development, toxicology and clinical operation.

By leveraging partnerships in China and advancing of IITs, Nona enables global biopharmaceutical partners to access established infrastructure and operational efficiency. This approach facilitates faster clinical trial initiation while maintaining high standards of global development and regulatory compliance.

"Expanding Nona's technology platforms and capabilities from antibody discovery to early clinic development represents a natural progression of our strategic vision. By combining our proprietary platforms with strategic external collaborations and internal development efforts, we are strengthening our ability to enable efficient clinical translation while remaining focused on building differentiated, scalable technologies," said Dr Di Hong, Chief Executive Officer, Nona Biosciences.